SILVIA PAPA | Course catalogue

SILVIA PAPA

Structure:

Dipartimento di SCIENZE CLINICHE INTERNISTICHE, ANESTESIOLOGICHE E CARDIOVASCOLARI

SSD:

MEDS-07/B

Profilo Research

Orari di ricevimento

Appuntamento da concordare previa richiesta tramite e-mail istituzionale

Curriculum

Nome / Cognome Silvia Papa

E-mail silvia.papa@uniroma1.it

Cittadinanza Italiana

Sesso femminile

Settore professionale Medico Chirurgo, Specialista in Cardiologia

ESPERIENZA PROFESSIONALE

Da Dicembre 2020 Dirigente Medico di I livello, a tempo determinato, presso il Policlinico Umberto I di Roma, in qualità di Cardiologo, nel Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche.

Dal 2010 ad oggi Attività di Ricerca presso il Centro di Ipertensione Polmonare del Dipartimento di Scienze Cardiovascolari e Respiratorie del Policlinico Umberto I di Roma (con il ruolo di: studentessa durante il percorso di Laurea, specializzanda, assegnista di Ricerca e Dottoranda, in atto).

Attività per la Regione Lazio come formatore per Corsi di Primo Soccorso Medico.

Vincitrice di un contratto di collaborazione presso l’Università di Roma “Sapienza”, Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche per lo svolgimento della seguente attività: gestione database internazionali in ipertensione polmonare.

Partecipazione come study-coordinator e sub-investigator in protocolli di ricerca internazionali, condotti secondo GCP.

Istruzione e formazione

Luglio 2002 Diploma di Maturità Scientifica con voto di 100/100, presso il Liceo Gregorio da Catino, Rieti.
31 ottobre 2008 Diploma di Laurea in Medicina e Chirurgia con voto 110/110 e lode, presso “Sapienza”, Università di Roma.
Marzo 2009 Esame di Stato per l’abilitazione all’esercizio della professione di Medico Chirurgo, Rieti.

23 marzo 2009 Iscritta all’Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri della Provincia di Rieti (n. 01629).

04 luglio2017 Specializzazione in Cardiologia con voto 70/70 e lode, Iˆ Cattedra di Cardiologia, presso “Sapienza Università di Roma”.
Giugno 2015 Certificato di BLSD (Basic Life Support-Defibrillation) “esecutore”, Roma.
Ottobre 2015 Certificato di BLSD (Basic Life Support-Defibrillation) “istruttore”, Roma.
Nel 2013–2014 -2015 Corso teorico-pratico di addestramento “Il test da sforzo cardiopolmonare (CPET)”, presso il Centro Cardiologico Monzino IRCCS..
Marzo 2014 Corso 2° theoretical and practical course: applications and developments of cardiopulmonary test and stress echocardiography in cardiology, San Donato Milanese.
Marzo 2015 Corso 3° theoretical and practical course: applications and developments of cardiopulmonary test and stress echocardiography in cardiology, San Donato Milanese.
Marzo 2015 Corso European Practicum on Cardiopulmonary Exercise Testing, Centro Cardiologico Monzino, IRCCS (Milano).
14-18/11/2016 Corso teorico-applicativo in Cardiorisonanza magnetica presso il Centro Cardiologico Monzino IRCCS.
Giugno 2016 Diploma in Cardiovascular Magnetic Resonance – Level 1 – rilasciato dall’European Association of Cardiovascular Imaging dell’European Society of Cardiology.

Da febbraio 2018 a dicembre 2020 Assegnista di Ricerca presso l’Università di Roma “Sapienza”, Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche.

Da Settembre 2018 Dottoranda di Ricerca in Fisiopatologia ed imaging cardio-toraco-vascolare (XXXIV ciclo) presso il Dipartimento di Scienze Cardiovascolari e Respiratorie dell’Università di Roma “La Sapienza”.

Capacità e competenze personali Negli ultimi 14 anni ha concentrato l’attività di ricerca nel campo dell’ipertensione polmonare e dello scompenso cardiaco

Attività di docenza

-Docente per il Corso di Laurea in Scienze Infermieristiche in convenzione con l’Università di Roma “Sapienza” con sede presso l’Ospedale Villa Albani di Anzio, per l’insegnamento di “Basi anatomo patologiche del corpo umano”, dell’a.a. 2018/2019.

-Docente per il Corso di Laurea in Scienze Infermieristiche D, Università di Roma “Sapienza” e Aeronautica Militare, per l’insegnamento di “Basi anatomo patologiche del corpo umano”, dell’a.a.2019-2020 e 2020-2021.

-Docente per il MIUR (Ministero dell’Istruzione, dell’Università, e della Ricerca), per il Corso “Biologia con curvatura biometrica”. Roma, Maggio 2018.

-Docente nel Master di I livello nell’ambito delle “Malattie Rare” (maggio 2019).

Società scientifiche
Membro delle seguenti Società Scientifiche:
- Società Italiana di Cardiologia (S.I.C.).
- Italian Pulmonary Hypertension network (iPHNET).
Collaborazioni internazionali
-Collaboratore per la lettura centralizzata degli esami ecocardiografici del Registro statunitense REVEAL (The Registry to EValuate Early And Long-term pulmonary arterial hypertension disease management).
-Collaboratore per studi in corso sulla valutazione del ventricolo destro nell’ipertensione arteriosa polmonare mediante ecocardiografia e test cardioplomonare, in collaborazione con il Department of Physiology and Pathophysiology, Pulmonary Hypertension Clinic Erasmus Hospital, Free University of Brussels.
-Collaboratore per studi in corso sulla valutazione del ventricolo destro nell’ipertensione arteriosa polmonare mediante ecocardiografia e RMN, in collaborazione con la University of Arizona College of Medicine, Tucson, Arizona. Referent in sede Prof. Franz Rischard.

Trials Clinici internazionali Sub-investigator/Study Coordinator in studi clinici condotti secondo GCP:

• Study coordinator per il protocollo internazionale N° AC-055-302 (SERAPHIN): “A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients whit symptomatic pulmonary arterial hypertension”.

• Study coordinator per il protocollo internazionale N° AC-055-303 (SERAPHIN-OL): “Long- term single arm open-label extension study of the SERAPHIN study, to assess the safety and tolerability of ACT-064992 in patients with symptomatic pulmonary arterial hypertension”.

• Sub-investigator per il protocollo internazionale N° 12934 (PATENT-1): “Randomized, double-blind, placebo-controlled, multicentre, multi-national, study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)”.

• Sub-investigator per il protocollo internazionale N° 12935 (PATENT-2): “Long-term extension, multi-centre, multi-national, study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mgor 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)”.

• Study coordinator per il protocollo clinico internazionale N° CQTI571A2301 (IMPRES): “A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficay Study”.

• Study coordinator per il protocollo clinico internazionale N° RLX.CHF.003 (Pre-RELAX-AHF/RELAX– AHF): “A phase II/III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of relaxin in subjects With Acute Heart Failure”.

• Sub-investigator per il protocollo clinico internazionale TDE-PH-308 (FREEDOM-C2): “A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension”.

• Study coordinator per il protocollo clinico internazionale N° CQTI571A2301E1: “An extension study to CQTI571A2301 to evaluate the long-term safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES extension”.

• Study coordinator per il protocollo clinico internazionale N° CQTI571A2102: “A non randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-administered drugs sildenafil and bosentan in pulmonary arterial hypertension (PAH) patients”.

• Study coordinator per il protocollo clinico internazionale N° CQTI571A2102E1: “An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension”.

• Study coordinator per il protocollo clinico internazionale N° AMB112565 (AMBITION): “A randomized, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension”.

• Study coordinator per il protocollo clinico internazionale N° AMB110094 (VOLT): “A post-marketing observational surveillance programme for ambrisentan”.

• Study coordinator per il protocollo clinico SPHERIC: “Studio multicentrico, randomizzato, a doppio cieco, verso placebo, della durata di 16 settimane che valuta l’effetto del sildenafil nel trattamento di paziente con ipertensione polmonare associate a BPCO”.

• Sub-investigator per il protocollo clinico RAMSES: “Right ventricular reverse reModeling and hemodynamic improvement after add-on combination therapy (ambriSentan/PDE-5i) in PAH patientS (RAMSES)”.

• Sub-investigator per il protocollo clinico internazionale PULSE-PAH-004: “A phase 3, placebo controlled, double-blind, randomized, clinical study to determine efficacy, safety and tolerability of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with Pulmonary Arterial Hypertension (PAH): INOvation-1”.

• Sub-investigator nello studio Arena APD811-301: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH)-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

• Sub-investigator nello studio Arena APD811-302: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of initial ralinepag, ambrisentan and tadalafil combination therapy versus ambrisentan and tadalafil combination therapy in treatment naïve patients with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH).

• Sub-investigator nello studio AC-065B302: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, phase 3 study with open-label extension period to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension.

• Sub-investigator nello studio ALPHABET (Arterial Pulmonary Hypertension And Beraprost European Trial)(A double-blind, randomised, placebo-controlled, European multicentre study to investigate the efficacy of beraprost sodium 20 µg tablet oral route on exercise capacity and morbi-mortality in children and adult patients with Pulmonary Arterial Hypertension; RU55 100/1L03).

• Sub-investigator nello studio FREEDOM-C2 (TDE-PH-308) (16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension).

• Sub-investigator nello studio FREEDOM-EXT (TDE-PH-304) (Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension).

• Sub-Investigator nello studio PATENT-1 (Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral Riociguat -BAY63-2521- (1 mg, 1,5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension).

• Co-investigator nello studio CHEST-1 (Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral Riociguat -BAY63-2521- (1 mg, 1,5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension; Protocollo 11348).

• Co-Investigator nello studio RELAX-AHFA (Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure).

• Co-Investigator nello studio ASCEND-HF (Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure).

• Co-Investigator N° 12935 (PATENT-2): “Long-term extension, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)” dal 01-03-2009 al 01-06-2016.

• Co-Investigator CHEST-2 Study (Open Label, Multi-centre, Multi-national Study to Evaluate long term the Efficacy and Safety of Oral Riociguat -BAY63-2521- (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension) dal 01-07-2009 a oggi.

Progetti di Ateneo
Partecipante: Progetto di Ateneo Medie Attrezzature “Valutazione morfologica e funzionale del ventricolo destro nell'ipertensione polmonare: studio dell'adattamento ventricolare in fase pre-clinica e ruolo nella stratificazione prognostica del paziente”, assegnato il 06/11/2018. Delibera S.A. n. 340/18.

Partecipante: Progetto di Ateneo Grande “Validation of a New Specific Activity Scale for Assessing Cardiovascular Functional Class in Pulmonary Arterial Hypertension: advantages in prognostic stratification”, assegnato il 26/02/2019. (n. protocollo RG118164367CF399).

Riconoscimenti e Premi
Premio per i 10 migliori abstract presentati al Congresso Nazionale S.I.C. nel dicembre 2018, titolo abstract “Clinical Implications of Idiopathic Pulmonary Arterial Hypertension Phenotypes Defined by Cluster Analysis”.

Premio per le 15 migliori pubblicazioni presentate al Congresso Nazionale S.I.C. nel dicembre 2019, titolo pubblicazione “The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension”.

Pubblicazioni Scientifiche
1. Vizza CD, Badagliacca R, Poscia R, Gambardella C, Pezzuto B, Crescenzi E, Papa S, Fedele F. Unusual presentation for a patent ductus arteriosus. Eur Respir Rev. 2009;18(113):174-6.
2. Vizza CD, Letizia C, Badagliacca R, Poscia R, Pezzuto B, Gambardella C, Nona A, Papa S, Marcon S, Mancone M, Iacoboni C, Riccieri V, Volterrani M, Fedele F. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. Int J Cardiol. 2013 Jul 15;167(1):220-4. (IF 4.0).
3. Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, Mezzapesa M, Nocioni M, Sciomer S, Valli G, Cedrone N, Fedele F, Vizza CD. Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance. Cardiology. 2012;121(2):76-82.
4. Badagliacca R, Pezzuto B, Poscia R, Mancone M, Papa S, Marcon S, Valli G, Sardella G, Ferrante F, Iacoboni C, Parola D, Fedele F, Vizza CD. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant. 2012;31(4):364-72. (I.F. 8.0).
5. Riccieri V, Vasile M, Iannace N, Stefanantoni K, Sciarra I, Vizza CD, Badagliacca R, Poscia R, Papa S, Mezzapesa M, Nocioni M, Valesini G. Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. Rheumatology (Oxford). 2013 Aug;52(8):1525-8. (I.F. 5.2).
6. Badagliacca R, Poscia R, Pezzuto B, Papa S, Gambardella C, Francone M,Mezzapesa M, Nocioni M, Nona A, Rosati R, Sciomer S, Fedele F, Dario Vizza C. Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: Determinants and impact on pump function. J Heart Lung Transplant. 2015 Mar;34(3):381-9 (I.F. 8.7).
7. Badagliacca R, Poscia R, Pezzuto B, Nocioni M, Mezzapesa M, Francone M, Giannetta E, Papa S, Gambardella C, Sciomer S, Volterrani M, Fedele F, Dario Vizza C. Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. J Heart Lung Transplant. 2015 Mar;34(3):395-403. doi: 10.1016/j.healun.2014.11.002. Epub 2014 Nov 8. PubMed PMID: 25499139. (I.F. 8.7).
8. Badagliacca R, Reali M, Poscia R, Pezzuto B, Papa S, Mezzapesa M, Nocioni M, Valli G, Giannetta E, Sciomer S, Iacoboni C, Fedele F, Vizza CD. Right intraventricular dyssynchrony in idiopathic, heritable and anorexigen-induced pulmonary arterial hypertension: clinical impact and reversibility. JACC Cardiovasc Imaging. 2015 Jun;8(6):642-52. (I.F. 10.2)
9. Badagliacca R, Poscia R, Pezzuto B, Papa S, Pesce F, Manzi G, Giannetta E,Raineri C, Schina M, Sciomer S, Parola D, Francone M, Carbone I, Fedele F, Vizza CD. Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2016 Nov;35(11):1321-1329. (I. F. 7.6).
10. Badagliacca R, Papa S, Valli G, Pezzuto B, Poscia R, Manzi G, Giannetta E,Sciomer S, Palange P, Naeije R, Fedele F, Vizza CD. Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension. Chest. 2016 Dec;150(6):1313-1322. (I.F. 7.6)
11. Badagliacca R, Papa S, Valli G, Pezzuto B, Poscia R, Reali M, Manzi G,Giannetta E, Berardi D, Sciomer S, Palange P, Fedele F, Naeije R, Vizza CD. Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension. Eur Respir J. 2017 Jun 1;49(6). pii: 1601419. doi: 10.1183/13993003.01419-2016. Print 2017 Jun. PubMed PMID: 28572119. (I.F. 12.2)
12. Badagliacca R, Reali M, Poscia R, Pezzuto B, Papa S, Mezzapesa M, Nocioni M,Valli G, Giannetta E, Sciomer S, Iacoboni C, Fedele F, Vizza CD. Letter to the editor about the paper "Right ventricular dyssynchrony predicts clinical outcomes in patients with pulmonary hypertension" by Murata et al. Int J Cardiol. 2017 May 1;234:128. doi: 10.1016/j.ijcard.2017.01.081. PubMed PMID: 28285628. (I. F. 4.0).
13. Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, Manzi G,Gianfrilli D, Ciciarello F, Sciomer S, Biondi-Zoccai G, Torre R, Fedele F, Vizza CD. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2017 Oct 2. pii:S1053-2498(17)32041-7. (I. F. 8.4).
14. Badagliacca R, Ghio S, Correale M, Poscia R, Camporotondo R, Ferraretti A, Papa S, Pezzuto B, Petrone P, Torre R, Di Biase M, Novara P, Guida S, Vizza CD. Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients. Int J Cardiol. 2018 Nov 15;271:301-305. (I. F. 3.47)
15. Badagliacca R, Papa S, Poscia R, Pezzuto B, Manzi G, Torre R, Fedele F, Vizza CD. The importance of right ventricular function in patients with pulmonary arterial hypertension. Expert Rev Respir Med. 2018 Oct;12(10):809-815. (I. F. 0.86).
16. Badagliacca R, Papa S, Poscia S, Valli G, Pezzuto B, Manzi G, Torre R, Gianfrilli G, Sciomer S, Palange P, Naeije R, Fedele F, Vizza CD. The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. J Heart Lung Transplant. 2019 Mar;38(3):306-314. doi: 10.1016/j.healun.2018.11.015. (I. F. 8.0). Share the first authorship.
17. Valli G, Palange P, Badagliacca R, Papa S, Poscia R, Vizza CD. Exercise energy expenditure in patients with idiopathic pulmonary arterial hypertension: Impact on clinical severity and survival. Respir Physiol Neurobiol. 2019 Jun;264:33-39. doi: 10.1016/j.resp.2019.04.003. Epub 2019 Apr 6. (I. F. 1.59).
18. D'Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S, Sarubbi B, Russo MG, Vizza CD, Golino P, Naeije R. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. Chest. 2019 Sep 26. pii: S0012-3692(19)33935-2. doi: 10.1016/j.chest.2019.09.009. (I. F. 9.6)
19. Badagliacca R, Papa S, Matsubara H, Lang IM, Poscia R, Manzi G, Vizza CD. The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. Int J Cardiol.2020 Feb 15;301:183-189. doi: 10.1016/j.ijcard.2019.10.043. Epub 2019 Nov 13. (I. F. 3.2).

20. Badagliacca R, Rischard F, Papa S, Kubba S, Vanderpool R, Yuan JX, Garcia JGN, Airhart S, Poscia R, Pezzuto B, Manzi G, Miotti C, Luongo F, Scoccia G, Sciomer S, Torre R, Fedele F, Vizza CD. Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. J Heart Lung Transplant. 2020 Apr;39(4):310-320. (I. F. 7.8)

21. De Lazzari C, De Lazzari B, Iacovoni A, Marconi S, Papa S, Capoccia M, Badagliacca R, Vizza CD. Intra-aortic balloon counterpulsation timing: A new numerical model for programming and training in the clinical environment. Comput Methods Programs Biomed. 2020 Oct;194:105537. doi: 10.1016/j.cmpb.2020.105537. Epub 2020 May 15. PMID: 32425283; PMCID: PMC7228691. (I. F. 3.6).
22. Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S, Cedrone N, Fedele F, Naeije R, Vizza CD. Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2020 Sep;13(9):2054-2056. doi: 10.1016/j.jcmg.2020.04.005. Epub 2020 Jun 17. PMID: 32563644. (I. F. 12.74).
23. Badagliacca R, D'Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, Casu G, Confalonieri M, Corda M, Correale M, D'Agostino C, De Michele L, Galgano G, Greco A, Lombardi C, Manzi G, Mercurio V, Mulé M, Paciocco G, Papa S, Romeo E, Scelsi L, Stolfo D, Vitulo P, Naeije R, Vizza CD. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2020 Aug 28. doi: 10.1164/rccm.202004-1006OC. Epub ahead of print. PMID: 32857597. (I. F. 12.18).
24. Badagliacca R, Pezzuto B, Papa S, Poscia R, Manzi G, Pascaretta A, Miotti C, Luongo F, Scoccia G, Ciciarello F, Casu G, Sciomer S, Fedele F, Naeije R, Vizza CD. Right Ventricular Strain Curve Morphology and Outcome in Idiopathic Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2020 Oct 27:S1936-878X(20)30792-0. doi: 10.1016/j.jcmg.2020.08.017. Epub ahead of print. PMID: 33129726. (I. F. 12.74).
25. D'Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, Correale M, Ghio S, Greco A, Lattanzio M, Mercurio V, Paciocco G, Papa S, Prediletto R, Romeo E, Russo MG, Tayar A, Vitulo P, Vizza CD, Golino P, Naeije R.J. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant. 2020 Dec;39(12):1389-1397. doi: 10.1016/j.healun.2020.08.016. Epub 2020 Aug 28.PMID: 32933828 (I. F. 7.8).

26. Badagliacca R, Papa S, Rischard F. Multidimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping. J Heart Lung Transplant. 2020 Nov 7:S1053-2498(20)31826-X. doi: 10.1016/j.healun.2020.11.001. Epub ahead of print. PMID: 33243664. (I. F. 7.8)

27. Cattadori G, Di Marco S, Farina S, Limongelli G, Monda E, Badagliacca R, Papa S, Tricarico L, Correale M. Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):65-71. doi: 10.1177/2047487320951109. PMID: 33238743; PMCID: PMC7691627. (I. F. 5.86).
28. D'Alto M, Romeo E, Argiento P, D'Andrea A, Sarubbi B, Correra A, Scognamiglio G, Papa S, Bossone E, Calabrò R, Vizza CD, Russo MG Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. .Int J Cardiol. 2013 Apr 15;164(3):323-6. doi: 10.1016/j.ijcard.2011.07.009. Epub 2011 Jul 28.PMID: 21802156

Abstract
1. Badagliacca, R; Papa, S; Manzi, G ; Poscia, R; Pezzuto, B; Minnucci, M; Pascaretta, A; Miotti, C; Luongo, F; Sciomer, S; Torre, R; Ciciarello, F; Cedrone, N; Fedele, F; Naeije, R; Vizza, CD. Adding right ventricular reverse remodeling criteria to risk assessment scores in pulmonary arterial hypertension. EUROPEAN HEART JOURNAL SUPPLEMENTS. Volume: 21. Pages: J76-J77. Meeting Abstract. Published: DEC 2019

2. Badagliacca, R; Pezzuto, B; Miotti, C; Papa, S; Poscia, R; Manzi, G; Pascaretta, A; Luongo, F; Torre, R; Casu, G; Sciomer, S; Fedele, F; Naeije, R; Vizza, CD. Clinical impact of right ventricular diastolic patterns in idiopathic pulmonary arterial hypertension by speckle traiking echocardiography. EUROPEAN HEART JOURNAL SUPPLEMENTS. Volume: 21. Pages: J76-J76. Meeting Abstract. Published: DEC 2019

3. D'Alto, M; Romeo, E; Argiento, P; Badagliacca, R; Papa, S; Farro, A; Sarubbi, B; Russo, MG; Vizza, CD; Golino, P. Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension EUROPEAN HEART JOURNAL. Volume: 40. Pages: 3037-3037. Supplement: 1. Meeting Abstract: 4972. Published: OCT 2019.

4. Badagliacca, R; Poscia, R; Pezzuto, B; Manzi, G; Papa, S; Minnucci, M; Torre, R; Sciomer, S; Fedele, F; Vizza, C. Echocardiography Predicts the Outcome in Pulmonary Arterial Hypertension Patients Treted With Parenteral Prostanoids. JOURNAL OF HEART AND LUNG TRANSPLANTATION. Volume: 37. Issue: 4. Pages: S206-S206. Meeting Abstract.

5. Badagliacca, R; Papa, S; Poscia, R; Valli, G; Pezzuto, B; Manzi, G; Palange, P; Fedele, F; Vizza, CD. Incremental Benefit of Cardiopulmonary Exercise Testing for the Prediction of Outcome in Stable Prevalent Pulmonary Arterial Hypertension Patients. JOURNAL OF HEART AND LUNG TRANSPLANTATION. Volume: 36. Issue: 4. Pages: S76-S76. Meeting Abstract: 178. Published: APR 2017

6. Badagliacca, R; Papa, S; Valli, G; Pezzuto, B; Poscia, R; Manzi, G; Sciomer, S; Fedele, F; Vizza, CD. Incremental benefit of echocardiographic imaging and cardiopulmonary exercise test in prognostic evaluation of idiopathic pulmonary arterial hypertension. EUROPEAN JOURNAL OF HEART FAILURE. Volume: 18. Pages: 123-123. Supplement: 1. Meeting Abstract: P491. Published: MAY 2016

7. Badagliacca, R; Poscia, R; Pezzuto, B; Mezzapesa, M; Nocioni, M; Papa, S; Francone, M; Sciomer, S; Iacoboni, C; Giannetta, E; Fedele, F; Vizza, C. Determinats and Prognostic Significance of Right Ventricular Reverse Remodeling in Idiopathic Pulmonary Arterial Hypertension Receiving Specific Medical Treatment. JOURNAL OF HEART AND LUNG TRANSPLANTATION. Volume: 34. Issue: 4. Pages: S116-S117.Meeting Abstract: 296. DOI: 10.1016/j.healun.2015.01.309. Published: APR 2015.

8. Badagliacca, R; Poscia, R; Pezzuto, B; Mezzapesa, M; Nocioni, M; Papa, S; Francone, M; Sciomer, S; Iacoboni, C; Giannetta, E; Fedele, F; Vizza, C. Concentric Hypertrophy Protects Against Clinical Worsening in Idiopathic Pulmonary Arterial: Hypertension: Insights From Magnetic Resonance Imaging. JOURNAL OF HEART AND LUNG TRANSPLANTATION. Volume: 34. Issue: 4. Pages: S117-S117. Supplement: S. Meeting Abstract: 297. DOI: 10.1016/j.healun.2015.01.310. Published: APR 2015

9. Valli, G; Badagliacca, R; Papa, S; Internullo, M; Poscia, R; Pezzuto, B; Nocioni, M; Mezzapesa, M; Pesce, F; Manzi, G; Palange, P; Vizza, C. Muscular Efficiency in Patients With Idiopathic Pulmonary Arterial Hypertension (iPAH): Impact on Clinical Severity and Survival. JOURNAL OF HEART AND LUNG TRANSPLANTATION. Volume: 34. Issue: 4.Pages: S339-S339. Supplement: S. Meeting Abstract: 947. DOI: 10.1016/j.healun.2015.01.966. Published: APR 2015

10. Badagliacca, R; Poscia, R; Pezzuto, B; Papa, S; Gambardella, C; Francone, M; Mezzapesa, M; Nocioni, M; Nona, A; Rosati, R; Sciomer, S; Fedele, F; Vizza, CD. Right Ventricular Dyssynchrony in Idiopathic Pulmonary Arterial Hypertension: Insights From Echocardiographic and Cardiac Magnetic Resonance Imaging. JOURNAL OF HEART AND LUNG TRANSPLANTATION. Volume: 33. Issue: 4. Pages: S229-S229. Supplement: S. Meeting Abstract: 617. DOI: 10.1016/j.healun.2014.01.594. Published: APR 2014

11. Badagliacca, R; Poscia, R; Nocioni, M; Mezzapesa, M; Francone, M; Pezzuto, B; Papa, S; Gambardella, C; Nona, A; Sciomer, S; Fedele, F; Vizza, CD. Right Ventricular Remodeling in Idiopathic Pulmonary Arterial Hypertension: Concentric Versus Eccentric Hypetrophy. JOURNAL OF HEART AND LUNG TRANSPLANTATION. Volume: 33. Issue: 4. Pages: S148-S148. Supplement: S. Meeting Abstract: 389. DOI: 10.1016/j.healun.2014.01.396. Published: APR 2014

12. Bruno, P; Vizza, CD; Ricci, A; Scozzi, D; Esposito, MC; Cherubini, E; Osman, GA; Papa, S; Nocioni, M; Mezzapesa, M; Mariotta, S. The dopaminergic system in pulmonary hypertension
EUROPEAN RESPIRATORY JOURNAL. Volume: 42. Supplement: 57. Meeting Abstract: 3098. Published: SEP 1 2013

13. Stefanantoni, K; Sciarra, I; Iannace, N; Vasile, M; Crescenzi, E; Papa, S; Poscia, R; Badagliacca, R; Vizza, CD ; Riccieri, V. SSc WITH AND WITHOUT PULMONARY ARTERIAL HYPERTENSION COMPARED TO IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION. DIFFERENT BEHAVIOUR OF SOME ANGIOGENETIC BIOMARKERS. RHEUMATOLOGY. Volume: 51. Pages: 116-116. Supplement: 2. Published: FEB 2012. Document Type:Meeting Abstract.

Partecipazione a stesura di libri di testo
Dal tromboembolismo venoso all’Ipertensione Polmonare Cronica Tromboembolica. In: Flebologia Emodinamica. S. Mandolesi. Società editrice Universo, I° Edizione 2010. Cap. 25.